about
Human dectin-1 deficiency and mucocutaneous fungal infectionsQuantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting.Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.Ertapenem for treatment of osteomyelitis: a case series.Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.Fungal Infections of the Bones and Joints.The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases.Candida infective endocarditis: an observational cohort study with a focus on therapyToll-like receptor 1 polymorphisms increase susceptibility to candidemia.Pharmacotherapy for human immunodeficiency virus-associated nephropathy.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Role of autophagy genetic variants for the risk of Candida infections.A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.Functional genomics identifies type I interferon pathway as central for host defense against Candida albicansCombination antifungal therapy: what can and should we expect?CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival.Current options in antifungal pharmacotherapy.The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infectionsCX3CR1-dependent renal macrophage survival promotes Candida control and host survival.Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.Evaluation of a digital microfluidic real-time PCR platform to detect DNA of Candida albicans in bloodRisk factors for group B streptococcal disease in neonates of mothers with negative antenatal testing.Human genetic susceptibility to Candida infections.An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility.Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity.Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications.Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients.Predictors of glycaemic control among HIV-positive veterans with diabetes.Circulating galectin-3 in infections and non-infectious inflammatory diseases.Pharmacological considerations in human immunodeficiency virus-infected adults in the intensive care unit.Mortality and time to extubation in severe hospital-acquired pneumonia.Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.The homozygous CX3CR1-M280 mutation impairs human monocyte survival.Autophagy is redundant for the host defense against systemic Candida albicans infections.Real-world implications of QT prolongation in patients receiving voriconazole and amiodaroneCollaborative Drug Therapy Management and Comprehensive Medication Management―2015Combination antifungal therapyFeasibility and Value of Developing a Regional Antibiogram for Community Hospitals
P50
Q24645008-5277EE7A-5458-4393-926B-54C299CC0308Q31114184-E85BADD5-DC58-42D4-B83E-602CD56A816BQ33913605-90413E11-C81E-417B-8A2B-4E318082677CQ34065412-13184DA7-F738-469D-A233-0832D8FB9BB0Q34111703-0F7830AA-0CF6-4A4C-A768-CFC78E50FDA2Q34370935-7C8AC518-7F01-4C2B-9C86-0690009FEC37Q34558300-18A748BB-5C26-4108-814F-9710C3110C09Q35168901-1C92FD4A-CBD5-43BD-B3F3-0B0E7F878663Q35765997-4CB10E75-9002-4E5A-A173-08FBE2449262Q36320626-AD0624C1-8D1A-41DC-99EF-30CBB72061E9Q36326220-5BEFE207-2251-48D5-BDFE-C6EF2029AC5DQ36394081-1175CB52-7B38-4AE8-B4F4-F5C69008CE7EQ36394086-E8342035-92B1-4071-9EB8-1AA3B5DAC5AFQ36762802-2C3783C9-9406-487C-94ED-8923F1484558Q36847555-A3DE4342-E40F-4284-A988-AE46D4B04290Q37078582-F25F1118-29FB-4F3F-90D4-CD1FB96CD93BQ37151326-6EB1A90E-62D9-4B62-8407-493CA50A312CQ37374119-4D55E06E-82EF-4D54-BD20-178E5B386AACQ37384004-4AECB3B9-7543-479C-8219-3AF478396F41Q37481373-059E89D3-6C11-4344-805D-894AA9871158Q37612516-D399BEAB-3458-4B73-B2BE-1468580F8D86Q37614189-0196C6D1-F624-4598-AA97-752BE6B1DE12Q38015881-CDFB6332-B89D-484E-8E25-09D06832E3DBQ38654393-ABFBD3C8-1ECF-4150-BFC1-26E92523D134Q39674877-21FB2FA2-BD99-404B-B5E8-F1376E0A6399Q40519821-809CD796-D323-4747-890C-AD0E3037BD1CQ41873407-2C6B7B3F-898F-435E-A8BE-1849265F4067Q42218775-4D20FFA9-0BFD-41A5-9172-EF63428BEFFEQ42256278-0AAB7AB7-8C75-4EC1-8C81-E2D025F2EFD7Q45351900-34FA18E3-CC49-42F8-B157-A185AC644FBEQ46332463-7513DAC0-3E03-4591-A51F-B5E3E82AB1EDQ46818343-7B7B92D1-35FE-4558-896B-6E198E770D56Q50130570-FB0CDB55-0086-497A-A256-9024B1D9B25FQ54645194-AB3705EF-FB02-416F-917E-00FA306485E0Q57181118-D0F0CCE0-D8E9-4273-9BFF-17D5C3373F34Q60016964-9D518B34-3B4F-47C5-89F0-2BB9005F9535Q76381447-0EE7462D-02B5-4D6F-A265-51B5472B66ACQ88432667-3E0EC04D-0329-4DF8-8B82-4AEE31B1CF48
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Melissa D Johnson
@nl
Melissa D Johnson
@sl
Melissa D. Johnson
@en
Melissa D. Johnson
@es
type
label
Melissa D Johnson
@nl
Melissa D Johnson
@sl
Melissa D. Johnson
@en
Melissa D. Johnson
@es
prefLabel
Melissa D Johnson
@nl
Melissa D Johnson
@sl
Melissa D. Johnson
@en
Melissa D. Johnson
@es
P106
P1153
18434236800
P21
P31
P496
0000-0002-6606-9460